SEARCH

SEARCH BY CITATION

References

  • Bacchi CJ, Nathan HC, Clarkson AB et al. (1990) Effect of ornithine decarboxylase inhibitors DL-α-difluoromethylornithine and α-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. American Journal of Tropical Medicine and Hygiene 33, 4652.
  • Bacchi CJ, Nathan HC, Livingston T et al. (1990) Differential susceptibility to DL-α-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrobial Agents and Chemotherapy 34, 11831188.
  • Bacchi CJ, Nathan HC, Yarlett N et al. (1994) Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-α-difluoromethylornithine and standard trypanocides. Antimicrobial Agents and Chemotherapy 38, 563569.
  • Fairlamb AH (1990) Novel approaches to the chemotherapy of trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 613617.
  • Fairlamb AH, Blackburn P, Ulrich P, Chait BT & Cerami A (1985) Trypanothione: a novel bis(glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 227, 14851487.
  • Iten M, Mett H, Evans A, Enyaru JCK, Brun R & Kaminsky R (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to DL-α- dilfuoromethylornithine. Antimicrobial Agents and Chemotherapy 41, 19221925.
  • Jennings FW (1988a) Chemotherapy of trypanosomiasis: the potentiation of melarsoprol by concurrent difluoromethylornithine (DFMO) treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 82, 572573.
  • Jennings FW (1988b) The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bulletin de la Société de Pathologie Exotique et de Ses Filiales 81, 595607.
  • Jennings FW (1990) Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination therapy and African trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 618621.
  • Jennings FW (1993) Combination therapy of CNS trypanosomiasis. Acta Tropica 54, 205213.
  • Khonde N, Pépin J & Mpia B (1997) A seven days course of eflornithine for relapsing T.b. gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 212213.
  • Legros D, Evans S, Maiso F, Enyaru JCK & Mbulamberi D (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 93, 439442.
  • Milord F, Loko L, Éthier L, Mpia B & Pépin J (1993) Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 473477.
  • Milord F, Pépin J, Loko L, Éthier L & Mpia B (1992) Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340, 652655.
  • Moore M & Richer M (2001) Re-emergence of epidemic sleeping sickness in southern Sudan. Tropical Medicine and International Health 6, 342347.
  • Pépin J, Khonde N, Maiso F et al. (2000) Short-course eflornithine in Gambian sleeping sickness: a multicentre randomised controlled trial. Bulletin of the World Health Organization 78, 12841295.
  • Pépin J & Méda H (2001) The epidemiology and control of African trypanosomiasis. Advances in Parasitology 49,71132.
  • Pépin J & Milord F (1994) The treatment of human African trypanosomiasis. Advances in Parasitology 33, 147.
  • Pépin J, Milord F, Khonde A, Niyonsenga T, Loko L & Mpia B (1994) Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Transactions of theRoyal Society of Tropical Medicine and Hygiene 88, 447452.
  • Simarro PP & Asumu PN (1996) Gambian trypanosomiasis and synergism between melarsoprol and eflornithine: first case report. Transactions of the Royal Society of Tropical Medicine and Hygiene 90, 315.
  • Stanghellini A & Josenando T (2001) The situation of sleeping sickness in Angola: a calamity. Tropical Medicine and International Health 6, 330334.
  • Wang CC (1995) Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annual Review of Pharmacology and Toxicology 35, 93127.
  • WHO (2001) Companies offer more help for the control of sleeping sickness. TDR News 65, 10.